Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study

Jean-Marie Rakic,1 Anita Leys,2 Heidi Brié,3 Kris Denhaerynck,4 Christy Pacheco,4 Stefaan Vancayzeele,3 Christine Hermans,3 Karen MacDonald,4 Ivo Abraham4,5 1Department of Ophthalmology, Centre Hospitalier Universitaire de Liège, Site du Sart Tilman, Liège, Belgium;...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Rakic JM, Leys A, Brié H, Denhaerynck K, Pacheco C, Vancayzeele S, Hermans C, MacDonald K, Abraham I
Format: article
Langue:EN
Publié: Dove Medical Press 2013
Sujets:
Ophthalmology
RE1-994
Accès en ligne:https://doaj.org/article/68dbf74850fd47c7805c8811c89e837e
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/68dbf74850fd47c7805c8811c89e837e

Documents similaires